Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and
potentially as good as or better than standard chemotherapy drugs, when given to subjects
with non-small cell lung cancer, who are 70 years of age or older.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital